Abstract
Stem cell-based therapy is one of the therapeutic options with promising results in the treatment of diabetes. Stem cells from various sources are expanded and induced to generate the cells capable of secreting insulin. These insulin-producing cells [IPCs] could be used as an alternative to islets in the treatment of patients with diabetes. Soluble growth factors, small molecules, geneencoding transcription factors, and microRNAs [miRNAs] are commonly used for the induction of stem cell differentiation. MiRNAs are small non-coding RNAs with 21-23 nucleotides that are involved in the regulation of gene expression by targeting multiple mRNA targets. Studies have shown the dynamic expression of miRNAs during pancreatic development and stem cell differentiation. MiR- 7 and miR-375 are the most abundant miRNAs in pancreatic islet cells and play key roles in pancreatic development as well as islet cell functions. Some studies have tried to use these small RNAs for the induction of pancreatic differentiation. This review focuses on the miRNAs used in the induction of stem cells into IPCs and discusses their functions in pancreatic β-cells.
Keywords: Diabetes, stem cells, pancreatic differentiation, MicroRNAs, insulin-producing cells, islet-like clusters.
Current Stem Cell Research & Therapy
Title:The Role of MicroRNAs in the Induction of Pancreatic Differentiation
Volume: 16 Issue: 2
Author(s): Elham Sabouri, Alireza Rajabzadeh, Seyedeh Elnaz Enderami, Ehsan Saburi, Fatemeh Soleimanifar, Ghasem Barati, Mohamad Rahmati, Gholamreza Khamisipour*Seyed Ehsan Enderami*
Affiliation:
- Department of Hematology, School of Allied Medical Sciences, Bushehr University of Medical Sciences, Bushehr,Iran
- Diabetes Research Center, Department of Medical Biotechnology, Faculty of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: Diabetes, stem cells, pancreatic differentiation, MicroRNAs, insulin-producing cells, islet-like clusters.
Abstract: Stem cell-based therapy is one of the therapeutic options with promising results in the treatment of diabetes. Stem cells from various sources are expanded and induced to generate the cells capable of secreting insulin. These insulin-producing cells [IPCs] could be used as an alternative to islets in the treatment of patients with diabetes. Soluble growth factors, small molecules, geneencoding transcription factors, and microRNAs [miRNAs] are commonly used for the induction of stem cell differentiation. MiRNAs are small non-coding RNAs with 21-23 nucleotides that are involved in the regulation of gene expression by targeting multiple mRNA targets. Studies have shown the dynamic expression of miRNAs during pancreatic development and stem cell differentiation. MiR- 7 and miR-375 are the most abundant miRNAs in pancreatic islet cells and play key roles in pancreatic development as well as islet cell functions. Some studies have tried to use these small RNAs for the induction of pancreatic differentiation. This review focuses on the miRNAs used in the induction of stem cells into IPCs and discusses their functions in pancreatic β-cells.
Export Options
About this article
Cite this article as:
Sabouri Elham , Rajabzadeh Alireza , Enderami Elnaz Seyedeh , Saburi Ehsan , Soleimanifar Fatemeh , Barati Ghasem , Rahmati Mohamad , Khamisipour Gholamreza *, Enderami Ehsan Seyed *, The Role of MicroRNAs in the Induction of Pancreatic Differentiation, Current Stem Cell Research & Therapy 2021; 16 (2) . https://dx.doi.org/10.2174/1574888X15666200621173607
DOI https://dx.doi.org/10.2174/1574888X15666200621173607 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parathyroid Carcinoma Causing Mild Hyperparathyroidism in Neurofibromatosis Type 1: A Case Report and Systematic Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
Reviews on Recent Clinical Trials New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors
Current Pharmaceutical Design Application of Innate Immune Molecules for a New Class of Drugs: Infection, Inflammation and Beyond
Endocrine, Metabolic & Immune Disorders - Drug Targets The Computational Analysis of Single Nucleotide Associated with MicroRNA Affecting Hepatitis B Infection
MicroRNA Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
Current Alzheimer Research Oxidative Stress in the Hypothalamus: the Importance of Calcium Signaling and Mitochondrial ROS in Body Weight Regulation
Current Neuropharmacology Anti-cancer Drug Development: Computational Strategies to Identify and Target Proteins Involved in Cancer Metabolism
Current Pharmaceutical Design Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention
Current Signal Transduction Therapy Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews Expression and Purification of Exendin-4 Dimer in Escherichia coli and Its Interaction with GLP-1 Receptor In Vitro
Protein & Peptide Letters Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design The Role of Inflammatory and Cytokine Biomarkers in the Pathogenesis of Frailty Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Aging process, cognitive decline and Alzheimer`s disease: can strength training modulate these responses?
CNS & Neurological Disorders - Drug Targets